Exvade Biosciences
2022
Nassir Mokarram-Dorri
Ravi Bellamkonda, Tarun Saxena, Nassir Mokarram-Dorri
Exvade Bioscience is engaged in developing groundbreaking technologies to better monitor and treat malignant brain tumors. Their platform technology has received the Breakthrough Designation from the U.S. Food and Drug Administration (FDA) and has been supported by several grants from the National Institute of Health (NIH).
Success Story
Brain Tumor 'Pied Piper' Device Gains Breakthrough Status
“This was the first demonstration that you can engineer migration inside the body and move a tumor from point A to point B by design,” said Ravi Bellamkonda, the Vinik Dean of the Pratt School of Engineering at Duke University, who began the research while at Georgia Tech. “It was also the first demonstration of bringing the tumor to your drug rather than your drug going into the brain and killing valuable cells.”
Read the full story on the Pratt website.